Company Overview

Intelligent Bio Solutions Inc. is a publicly traded life sciences company focused on the development, manufacturing, and commercialization of rapid, non-invasive drug screening and detection solutions. The company operates primarily within the biotechnology, diagnostics, and workplace safety industries, offering testing technologies designed to detect drugs of abuse through oral fluid rather than traditional urine or blood-based methods. Its core value proposition centers on speed, portability, and ease of use for decentralized testing environments.

The company’s primary revenue driver is its proprietary oral-fluid testing platform, which is marketed to employers, law enforcement agencies, corrections facilities, and healthcare-related organizations seeking rapid drug screening solutions. Intelligent Bio Solutions Inc. positions itself as an alternative to laboratory-based testing by enabling point-of-care screening with minimal training and infrastructure. The company traces its origins to Australia and previously operated under the name GBS Inc., rebranding to Intelligent Bio Solutions Inc. as it refined its strategic focus and expanded its presence in the U.S. public markets.

Business Operations

Intelligent Bio Solutions Inc. conducts operations through its core operating business focused on drug screening technology and related consumables. The company generates revenue primarily through the sale of single-use oral fluid test cartridges and portable screening analyzers, supported by recurring demand from ongoing testing programs. Its business model emphasizes consumable-driven revenue, with instruments acting as an entry point for longer-term customer relationships.

Operations span both domestic and international markets, with research, product development, and manufacturing activities historically linked to Australia, while commercial and corporate activities are centered in the United States. The company operates through wholly owned subsidiaries, including Intelligent Bio Solutions Australia Pty Ltd., which supports manufacturing, research, and regional commercialization. Public disclosures indicate no material joint ventures; data on additional subsidiaries or partnerships is inconclusive based on available public sources.

Strategic Position & Investments

The company’s strategic direction is focused on expanding adoption of oral-fluid drug testing as an alternative to urine-based methods, particularly in safety-sensitive industries. Growth initiatives include increasing penetration in U.S. workplace testing markets, expanding international distributor relationships, and advancing regulatory and customer acceptance of its testing platform. Management has emphasized scalability through manufacturing efficiencies and expanded test menu capabilities.

Intelligent Bio Solutions Inc. has pursued selective investments aligned with product development and commercialization rather than large-scale acquisitions. Capital allocation has been directed toward technology refinement, regulatory compliance, and sales infrastructure. The company continues to evaluate emerging opportunities in rapid diagnostics and decentralized testing, though involvement in adjacent sectors beyond drug screening is limited based on publicly available disclosures.

Geographic Footprint

The company maintains its corporate headquarters in the United States, while operational and manufacturing activities have significant roots in Australia. Its products are marketed across North America, Australia, and parts of Europe, primarily through direct sales efforts and distribution partners. The U.S. represents the company’s largest target growth market due to the size of the workplace drug testing industry.

Internationally, Intelligent Bio Solutions Inc. maintains a growing commercial presence supported by regulatory approvals and distributor relationships. While its global footprint is modest compared to larger diagnostics firms, the company has positioned itself to expand in regions where rapid, point-of-care drug screening is increasingly adopted.

Leadership & Governance

Intelligent Bio Solutions Inc. is led by an executive team with experience in life sciences, diagnostics, and public company operations. Leadership has articulated a strategy centered on disciplined growth, regulatory credibility, and commercialization of differentiated technology. The board and management emphasize operational execution and capital efficiency as key governance priorities.

Key executives include:

• Harry Simeonidis – President & Chief Executive Officer
• John Wood – Chief Financial Officer
• Paul Dickson – Chief Operating Officer
• Kevin Young – Vice President, Sales & Marketing

The leadership team collectively oversees strategic planning, regulatory compliance, and market expansion, with a stated focus on establishing Intelligent Bio Solutions Inc. as a recognized provider of rapid drug screening solutions.